Drawing insights from the neuroprotective activities of 3K3A-APC in the brain and CNS [11,15,16,17] and recognizing the retina, particularly the macula, as an extension of the brain, we propose 3K3A-APC as a potential neuroprotective treatment for AMD and other neurodegenerative retinal pathologies. This evidence concerns the gene APC and age-related macular degeneration.